Welch MJ - Search Results

1

Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: Comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models.

O'Donoghue JA, Zanzonico P, Pugachev A, Wen B, Smith-Jones P, Cai S, Burnazi E, Finn RD, Burgman P, Ruan S, Lewis JS, Welch MJ, Ling CC, Humm JL. O'Donoghue JA, et al. Among authors: welch mj. Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1493-502. doi: 10.1016/j.ijrobp.2004.12.057. Int J Radiat Oncol Biol Phys. 2005. PMID: 15817355

2

Cell line-dependent differences in uptake and retention of the hypoxia-selective nuclear imaging agent Cu-ATSM.

Burgman P, O'Donoghue JA, Lewis JS, Welch MJ, Humm JL, Ling CC. Burgman P, et al. Among authors: welch mj. Nucl Med Biol. 2005 Aug;32(6):623-30. doi: 10.1016/j.nucmedbio.2005.05.003. Nucl Med Biol. 2005. PMID: 16026709

3

Tumor localization of 16beta-18F-fluoro-5alpha-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer.

Larson SM, Morris M, Gunther I, Beattie B, Humm JL, Akhurst TA, Finn RD, Erdi Y, Pentlow K, Dyke J, Squire O, Bornmann W, McCarthy T, Welch M, Scher H. Larson SM, et al. J Nucl Med. 2004 Mar;45(3):366-73. J Nucl Med. 2004. PMID: 15001675 Free article. Clinical Trial.

4

PET-based radiation dosimetry in man of 18F-fluorodihydrotestosterone, a new radiotracer for imaging prostate cancer.

Zanzonico PB, Finn R, Pentlow KS, Erdi Y, Beattie B, Akhurst T, Squire O, Morris M, Scher H, McCarthy T, Welch M, Larson SM, Humm JL. Zanzonico PB, et al. J Nucl Med. 2004 Nov;45(11):1966-71. J Nucl Med. 2004. PMID: 15534070 Free article. Clinical Trial.

5

Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response-a preliminary report.

Dehdashti F, Grigsby PW, Mintun MA, Lewis JS, Siegel BA, Welch MJ. Dehdashti F, et al. Among authors: welch mj. Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1233-8. doi: 10.1016/s0360-3016(02)04477-2. Int J Radiat Oncol Biol Phys. 2003. PMID: 12654432

6

Enhancing targeted radiotherapy by copper(II)diacetyl- bis(N4-methylthiosemicarbazone) using 2-deoxy-D-glucose.

Aft RL, Lewis JS, Zhang F, Kim J, Welch MJ. Aft RL, et al. Among authors: welch mj. Cancer Res. 2003 Sep 1;63(17):5496-504. Cancer Res. 2003. PMID: 14500386

7

An imaging comparison of 64Cu-ATSM and 60Cu-ATSM in cancer of the uterine cervix.

Lewis JS, Laforest R, Dehdashti F, Grigsby PW, Welch MJ, Siegel BA. Lewis JS, et al. Among authors: welch mj. J Nucl Med. 2008 Jul;49(7):1177-82. doi: 10.2967/jnumed.108.051326. Epub 2008 Jun 13. J Nucl Med. 2008. PMID: 18552145 Free PMC article.

8

PET imaging of hypoxia.

Lewis JS, Welch MJ. Lewis JS, et al. Among authors: welch mj. Q J Nucl Med. 2001 Jun;45(2):183-8. Q J Nucl Med. 2001. PMID: 11476169 Review.

9

Assessing tumor hypoxia in cervical cancer by PET with 60Cu-labeled diacetyl-bis(N4-methylthiosemicarbazone).

Dehdashti F, Grigsby PW, Lewis JS, Laforest R, Siegel BA, Welch MJ. Dehdashti F, et al. Among authors: welch mj. J Nucl Med. 2008 Feb;49(2):201-5. doi: 10.2967/jnumed.107.048520. Epub 2008 Jan 16. J Nucl Med. 2008. PMID: 18199612 Free article.

10

Autoradiographic and small-animal PET comparisons between (18)F-FMISO, (18)F-FDG, (18)F-FLT and the hypoxic selective (64)Cu-ATSM in a rodent model of cancer.

Dence CS, Ponde DE, Welch MJ, Lewis JS. Dence CS, et al. Among authors: welch mj. Nucl Med Biol. 2008 Aug;35(6):713-20. doi: 10.1016/j.nucmedbio.2008.06.001. Nucl Med Biol. 2008. PMID: 18678357 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

642 results

Search Page